Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 44 Publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MXLLbY5ie2ViQYPzZZk> NFjjZYRKdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MljTNVI3PDZyMUm=
3T3 M3XzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlraTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgbY5lfWOnZDCzWFMh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAyKM7:TR?= MWmxNlY1PjBzOR?=
3T3 MVfGeY5kfGmxbjDBd5NigQ>? NF3CeHhKdmirYnn0bY9vKG:oIG\hd4N2dGG{IHXu[I91cGWuaXHsJIdzd3e2aDDmZYN1d3JicnXj[ZB1d3Jid3n0bEBKSzVyIH;mJFAvODVizszN NEDveogyOjZ2NkCxPS=>
3T3 M3fWT2tqdmG|ZTDBd5NigQ>? NH32[24zOCCvaX6= MmPnSG1UVw>? M1HlRmNmdGy3bHHyJIlvcGmkaYTpc44hd2ZiVlXHSkBqdmS3Y3XkJIh2dWGwIFvEVkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKyJO69VQ>? NWrFSo5tOTZzNkKwNFg>
NIH3T3 M4TWW2tqdmG|ZTDBd5NigQ>? MVqyNEBucW5? M{LYVGROW09? NWjRNZZNcW6qaXLpeEBpfW2jbjDLSHIhc2mwYYPlJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6wNVgh|ryP MnruNVYyPjJyMEi=
A549 M{CwXWZ2dmO2aX;uJGF{e2G7 MU\EUXNQ MnvKTY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hSTV2OTDj[YxtKG2rZ4LheIlwdiC5aYToJGlEPTBib3[gNkDPxE1? MkPDNVg1OzRzNEW=
DU145 M1joTmZ2dmO2aX;uJGF{e2G7 NIPQ[2lFVVOR M4myUGlvcGmkaYTpc44hd2ZiYz3N[ZQh\GWyZX7k[Y51KEiJRj3pcoR2[2WmIHj1cYFvKESXMUS1JINmdGxic3PheJRmemmwZzD3bZRpKEmFNUCgc4YhOTBizszN Mm[3NVg1OzRzNEW=
KB3-1 MVLDfZRwfG:6aXOgRZN{[Xl? Mn;tO|IhcA>? NVrWe21TTE2VTx?= M1;DO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\3BvbnXnZZRqfmViS1KtN{0yKGOnbHzzJJdqfGhiSVO1NEBw\iB{LkOg{txO NIewO44yQTN7N{OyNi=>
KBV1 NXzVdm9IS3m2b4TvfIlkKEG|c3H5 M1vUZVczKGh? NHPEeppFVVOR Mlr3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1odHmlb4Dyc5RmcW5vZYjwdoV{e2mwZzDLRnYyKGOnbHzzJJdqfGhiSVO1NEBw\iB2LkGg{txO M2PY[VE6Ozl5M{Ky
A375 NYnzPYQyS3m2b4TvfIlkKEG|c3H5 NFn0PZY4OiCq Mn\XSG1UVw>? MV3JR|UxRTVwNDFOwG0> M2nT[FE6PjV2NEC4
RS4-11 Mne3SpVv[3Srb36gRZN{[Xl? MlTCNkBp M2\zUmlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQTlizszN NYDVeVJQOTl4NUS0NFg>
RS4-11 NYfBd4FUTnWwY4Tpc44hSXO|YYm= MVqyJIg> NHH3RWVKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB|NDFOwG0> NX3BNnV5OTl4NUS0NFg>
Sf9 NEn6TmJMcW6jc3WgRZN{[Xl? M3\lZVMxKG2rbh?= Mn7YTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIG\FS2ZTKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4yQDVizszN M1ixfVE6QDV2MEWx
Ba/F3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3iO|IhcA>? NW\UcJhPUUN3ME2xMlIh|ryP MYiyNFEyPzByNB?=
BaPTC2 NHv5b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[3[VczKGh? MlXITWM2OD1yLkKyJO69VQ>? Mn;4NlAyOTdyMES=
Sf9 MVPGeY5kfGmxbjDBd5NigQ>? NF:wVIQyKGh? MoWxSG1UVw>? NV3E[mhPUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJHJGXCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOyEQvF2= NETzRmczODFzN{CwOC=>
H4 Mn7OR5l1d3SxeHnjJGF{e2G7 NFn2OFcyOCEQvF2= NYPp[I1JXG:6aXPpeJkhcW5iaIXtZY4hUDRiY3XscJM> NHX2OXAzODN3MEiwOi=>
SF-539 M17k[GtqdmG|ZTDBd5NigQ>? MVmzN|Mh|ryP NXjqeoVxPjBibXnu NGja[WtFVVOR NGfUcG1KdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEzNjJizszN NWLWZYFsOjB2MEO3NFA>
U251 NF7OWo5McW6jc3WgRZN{[Xl? MVGzN|Mh|ryP Mn;yOlAhdWmw NEnMO3lFVVOR M33yUmlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMUiuPUDPxE1? NEHjd5gzODRyM{ewNC=>
A431 NXvofFRRU2mwYYPlJGF{e2G7 MYDJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN M3LqVlIxPTV6MEey
A431 MYDLbY5ie2ViQYPzZZk> NX;LTGZMUW6qaXLpeIlwdiCxZjDWSWdHWjJiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyQC57IN88US=> MYKyNFU2QDB5Mh?=
HepG2 NVH1PGloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT6O|IhcA>? MXTJR|UxRTNwOEGg{txO M13ySVIxPTdyNUK2
Kasumi-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jJT|czKGh? NInDbGZKSzVyPUCuNFE3KM7:TR?= NW\mSHhMOjB3N{C1NlY>
RS4-11 M{n4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET0c|M4OiCq MV7JR|UxRTFizszN M1L1VVIxPTdyNUK2
THP1 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXq3NkBp MmLaTWM2OD1yLkWg{txO MojQNlA2PzB3Mk[=
Kasumi-1 NWi5XJRuTnWwY4Tpc44hSXO|YYm= MknvTY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= NXPlOZpHOjB6M{OwN|k>
A549 NHfkV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnlbpAyPiCq MorXRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\Wyucx?= MoHhNlE1PTB2NkO=
HL60 M1H1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKwNVYhcA>? MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy| MnvsNlE1PTB2NkO=
HUVEC NELheodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXJb2cyPiCq NWHhc2pnUW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCyMlc2KM7:TR?= M2q1TFIyPDVyNE[z
HUVEC M{nPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13US|E3KGh? MVPJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO M1XKVFIyPDVyNE[z
IM9 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fze|E3KGh? NHjhTVFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJUVkh[2WubIO= NWLZZ|hQOjF2NUC0OlM>
K562 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jEWVE3KGh? NYTrRZAxSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsdy=> MXWyNVQ2ODR4Mx?=
MDA-MB-231 M1vLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL1cHJyOTZiaB?= Moq2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[Yxtew>? MmXwNlE1PTB2NkO=
H460 NYXycFRYS3m2b4TvfIlkKEG|c3H5 NVjOXlhLPzJiaB?= NXvCNFI1UUN3ME2yMlch|ryP NH\iNFQzOTZ{MUi4NC=>
SMMC7721 MmfoR5l1d3SxeHnjJGF{e2G7 NFnPR404OiCq M1;xVGlEPTB;Nj60O{DPxE1? MnS1NlE3OjF6OEC=
WI38 NFfqWGhEgXSxdH;4bYMhSXO|YYm= NHfhXZM4OiCq Mm\mTWM2OD16LkW2JO69VQ>? NInjSmYzOTZ{MUi4NC=>
HEK293 M1vOVGtqdmG|ZTDBd5NigQ>? NX;1ToFtOTByIH7N MmHJNUBp M2fCVYRw\XNibn;0JIlvcGmkaYSgWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25ib3[geJlzd3OrbnWgNVE4PSC{ZYPp[JVmKG:wIG\FS2ZTOiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{ NYXMOpJqOjF6OEWyPFc>
HUVEC NILhTJJHfW6ldHnvckBCe3OjeR?= M2PJbFEh|ryP MojvNlQhcA>? NXTLSJk1SW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iVlXHSk1qdmS3Y3XkJINmdGxibXnndoF1cW:w NVfBeXN2OjF7NkOzNFU>
HUVEC NG\TZplHfW6ldHnvckBCe3OjeR?= MX6xJO69VQ>? NG[3TZAyKGh? MmS2TY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE MlXwNlE6PjN|MEW=
HUVEC MVPGeY5kfGmxbjDBd5NigQ>? MkW2NUDPxE1? NWj5ToprOSCq M2C4bmlvcGmkaYTpc44hd2ZiZV7PV{BxcG:|cHjvdplt[XSrb36gZZQhW2W{LUGxO|IhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD MU[yNVk3OzNyNR?=
HUVEC MV7LbY5ie2ViQYPzZZk> NYPJeWlpOSEQvF2= MmLyNUBp M4i3TWlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckBifCC2eYKtNVE4PSCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> M{jLXFIyQTZ|M{C1
HUVEC NYTmVmRGTnWwY4Tpc44hSXO|YYm= NFHoV48yKM7:TR?= NUTRU3VLOSCq MWjkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= NX\G[GpxOjF7NkOzNFU>
HL60 Ml65R5l1d3SxeHnjJGF{e2G7 Ml7uOVAh|ryP NWLrSpprPDhiaB?= M4K2TGROW09? MkHKTWM2OD1zNT61JO69VQ>? NIjXeGszOjBzOUG4PC=>
K562 M3zJfGN6fG:2b4jpZ{BCe3OjeR?= NWDOfIZ6PTBizszN NHXHe2M1QCCq MnHmSG1UVw>? NVraSppzUUN3ME2yNU46KM7:TR?= Mn60NlIxOTlzOEi=
PC3 NVnP[Ys5S3m2b4TvfIlkKEG|c3H5 NWfFVFE1PTBizszN MlHKOFghcA>? Mnv1SG1UVw>? MkLaTWM2OD1{NT6xJO69VQ>? M2r3T|IzODF7MUi4
SF-539 M3uxeWtqdmG|ZTDBd5NigQ>? MkXwN|M{KM7:TR?= NHnLelY3OCCvaX6= NVrn[o4xUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgeJlzd3OrbnWgb4lv[XOnIHHjeIl3cXS7IHnuJHBFT0ZvQlKtd5RqdXWuYYTl[EBpfW2jbjDTSk02OzliY3XscJMhf2m2aDDJR|UxKG:oIEGyMlIh|ryP MmTJNlIzODR5NEG=
HAEC M1WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjkbW4yODBizszN NUW5VpFGPzJiaB?= M3;pe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFHFR{Bk\WyuczDlfJBz\XO|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjFizszN M4fwe|IzPDR2Nke5
HT-29 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD6eG8yODBizszN NXfxNmMyPzJiaB?= NHfQRm1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwM{Og{txO MnHmNlI1PDR4N{m=
MV4-11 NUDneW81S3m2b4TvfIlkKEG|c3H5 M1nZVFczKGh? NX23dVVIUUN3ME2wMlAxOyEQvF2= MUCyNlQ2OjVzOB?=
HepG2 NELRV2hEgXSxdH;4bYMhSXO|YYm= NYn6T|hmPDhiaB?= MljuTWM2OD1zMz6yOEDPxE1? NWXvO3RYOjJ2OEO2NFg>
PC9 NYLIWJNzS3m2b4TvfIlkKEG|c3H5 MVW0PEBp NVrIWVBoUUN3ME2xNE46PyEQvF2= MmDKNlI1QDN4MEi=
CAKI-1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[zb|ExOCEQvF2= MnnqOFghcA>? M3mxS2ROW09? MlvrS2k2OD1yLk[zJO69VQ>? MUCyNlU3ODZ{Nx?=
EKVX MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO5UZYyODBizszN MX60PEBp NU\vXmgyTE2VTx?= NYTRUpl7T0l3ME23Mlkh|ryP M4i2U|IzPTZyNkK3
MCF7 NVrJbmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVOHYyODBizszN NXviflBUPDhiaB?= M2TjZ2ROW09? NFvmeXpIUTVzPUKg{txO NGPwRWkzOjV4ME[yOy=>
MDA-MB-435 NG\Z[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNFAh|ryP NWXWVm9CPDhiaB?= M{\Dc2ROW09? MWXHTVUzRTJizszN NGrnOGczOjV4ME[yOy=>
OVCAR3 NX\rRoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[5[GkyODBizszN MmXzOFghcA>? NUTDOHF7TE2VTx?= MV\HTVU{RTNwMjFOwG0> M3fETFIzPTZyNkK3
SNB19 M3XGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[zPVExOCEQvF2= M1\MfVQ5KGh? NF7wSGFFVVOR MXPHTVU1RTFyIN88US=> NFH2cZczOjV4ME[yOy=>
SW620 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNFAh|ryP NXG4OYVMPDhiaB?= MVvEUXNQ NIG2eJhIUTV3PUGuN{DPxE1? MYiyNlU3ODZ{Nx?=
TK10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCxSmFtOTByIN88US=> NWjmUFFWPDhiaB?= M2i3PGROW09? MnK3S2k2Pj14LkOg{txO NXLZdoV4OjJ3NkC2Nlc>
UACC257 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\1VVAyODBizszN MkD1OFghcA>? NGn0T4tFVVOR MoW3S2k2Pz12IN88US=> M1HCPVIzPTZyNkK3
HAEC M3W0S2N6fG:2b4jpZ{BCe3OjeR?= NETheFkyODBizszN NEfadYE4OiCq MWDEUXNQ Ml7mR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BJSUWFIIfpeIghUUN3MDDv[kAxNjFizszN MoHjNlMyOzF3NEG=
HT-29 NGj0Nm5EgXSxdH;4bYMhSXO|YYm= M4ez[|ExOCEQvF2= MUW3NkBp NVG2ZY5xTE2VTx?= M3LVVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KF[HR1\SJIV5eHKnc4PpcochcHWvYX6gTHQuOjliY3XscJMhf2m2aDDJR|UxKG:oIECuN|Mh|ryP NUDjfFltOjNzM{G1OFE>
HCT116 MofuSpVv[3Srb36gRZN{[Xl? MkLINlQhcA>? M3;xTWROW09? Mnr0RY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygcYloemG2aX;u MnPzNlMyPTN{MEC=
HUVEC MWHGeY5kfGmxbjDBd5NigQ>? MX[yJO69VQ>? MmHjNVghcA>? NWGyVG1KTE2VTx?= MoXJRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUO|IIXu[IVzKGi7cH;4bYMh[2:wZHn0bY9vKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWkZTDmc5Ju[XSrb36= Mmn6NlMyPTN{MEC=
ACHN M{LYd2N6fG:2b4jpZ{BCe3OjeR?= MkHuOkBl Mon3TWM2OD1{LkWg{txO NIHZcpEzOzN4MEGwOC=>
A498 MV\DfZRwfG:6aXOgRZN{[Xl? M3S3RlExOCEQvF2= M{S1Z|czKGh? NXPZfpA2TE2VTx?= MW\JR|UxRTRwMzFOwG0> NWDo[4dKOjN2OEm2NlY>
HUVEC MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[zJO69VQ>? NHrwSYMzPCCq NHK0W|NFVVOR Ml;URY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> NYnSNndEOjN3OEO5NVE>
HUVEC MkTST4lv[XOnIFHzd4F6 MnftNlAxKM7:TR?= M4TDfGROW09? MnXPTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= NF;yb4UzOzV6M{mxNS=>
HUVEC MYPLbY5ie2ViQYPzZZk> Mnv0NlAxKM7:TR?= MlnPSG1UVw>? MVjJcohq[mm2aX;uJI9nKF[HR1\SNUBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF NIPOPVczOzV6M{mxNS=>
A549 Mkj1R5l1d3SxeHnjJGF{e2G7 NFnMfXc4OiCq NEG2S2VFVVOR NYfhb5dlUUN3ME2yMlQ1KM7:TR?= MkX0NlM3ODJ2NEG=
HCT116 MonIR5l1d3SxeHnjJGF{e2G7 NHT1eIE4OiCq MUjEUXNQ M2XKPGlEPTB;ND63NUDPxE1? MWmyN|YxOjR2MR?=
MCF7 M3XFXWN6fG:2b4jpZ{BCe3OjeR?= MoTHO|IhcA>? MXPEUXNQ NEDMTXRKSzVyPU[uNlkh|ryP NHPEUVMzOzZyMkS0NS=>
BGC NGPGOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3NkBp MlW4SG1UVw>? MoOyTWM2OD12Lke4JO69VQ>? MWOyN|k6QTB2MB?=
BxPC3 NXLtVohET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorWO|IhcA>? MoTtSG1UVw>? MnTkTWM2OD1|Lk[zJO69VQ>? MUOyN|k6QTB2MB?=
HT-29 NGnsNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTsO|IhcA>? NFTMXJhFVVOR M3\6TWlEPTB;MT60O{DPxE1? M2nt[lI{QTl7MESw
T24 M1;pN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nFcVczKGh? NX3RSYl7TE2VTx?= NYm0cGN2UUN3ME2yMlQ1KM7:TR?= NWXu[4tvOjN7OUmwOFA>
4T1 MWrDfZRwfG:6aXOgRZN{[Xl? NYPQfWl1PzJiaB?= M{CxSWROW09? NXXt[2RVUUN3ME2wMlAyPiEQvF2= NUPVZlZKOjR6OUC2OVI>
MCF7 NYjiVlF4S3m2b4TvfIlkKEG|c3H5 MXe3NkBp NYizbYprTE2VTx?= NXPlNnZbUUN3ME2wMlAzPzFizszN MWGyOFg6ODZ3Mh?=
MCF7 MWrDfZRwfG:6aXOgRZN{[Xl? MlizO|IhcA>? MV7EUXNQ NGL0S4lKSzVyPUCuNFI6OyEQvF2= NVLKOoNPOjR6OUC2OVI>
MDA-MB-231 NHfOdllEgXSxdH;4bYMhSXO|YYm= MlPIO|IhcA>? NETvSYxFVVOR MVjJR|UxRTBwMEKyN{DPxE1? NIrRSmMzPDh7ME[1Ni=>
MDA-MB-435 M33sWmN6fG:2b4jpZ{BCe3OjeR?= NWDzblBLPzJiaB?= NHLENVFFVVOR M2XLcmlEPTB;MD6wNFk4KM7:TR?= NGfDb5MzPDh7ME[1Ni=>
MDA-MB-468 NVTneJM4S3m2b4TvfIlkKEG|c3H5 MmT2O|IhcA>? Mni4SG1UVw>? MXLJR|UxRTBwMEC2NUDPxE1? MofxNlQ5QTB4NUK=
A431 MljST4lv[XOnIFHzd4F6 M1jIb|ExKM7:TR?= NGXnfpcyKGh? NYG0Om5XTE2VTx?= NF33VXlKdmirYnn0bY9vKG:oIFXHSnIhf2m2aDDJR|UxKG:oIECuNVczOSEQvF2= MoHpNlQ5QTB4NUK=
SH-SY5Y Mo[0T4lv[XOnIFHzd4F6 MX6xNEDPxE1? NEH2V4syKGh? MYDEUXNQ NWfTUmhmUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGge4l1cCCLQ{WwJI9nKDBwMEizNUDPxE1? NWTUcncxOjR6OUC2OVI>
U251 NUHnRnVyU2mwYYPlJGF{e2G7 MX[xNEDPxE1? MVGxJIg> MV7EUXNQ NWWw[Xl1UW6qaXLpeIlwdiCxZjDWSWdHWjJid3n0bEBKSzVyIH;mJFAvODF6OTFOwG0> MX[yOFg6ODZ3Mh?=
Bel7402 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK0OVlvPzJiaB?= NUDVWZdlTE2VTx?= MlT1TWM2OD1{Lk[3JO69VQ>? MX[yOFkxPDl4MR?=
HK2 NEnkXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHMO|IhcA>? MUDEUXNQ MYLJR|UxRTVwOEWg{txO MWeyOFkxPDl4MR?=
LO2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG0Rm9uPzJiaB?= M{jlV2ROW09? MUjJR|UxRTF7LkmzJO69VQ>? MUGyOFkxPDl4MR?=
MV4-11 NVTZU5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi0PEBp M2DzVmROW09? NWD3RZZTUUN3ME2wMlAxOyEQvF2= MX6yOFkxPDl4MR?=
NCI-H3122 NFrEWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f2dFczKGh? NH7iXmpFVVOR M{L1PWlEPTB;MD64N{DPxE1? M4D0clI1QTB2OU[x
NCI-H460 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLVcXo4OiCq NH3Yd|NFVVOR Mo\ITWM2OD12LkOxJO69VQ>? MkTWNlQ6ODR7NkG=
NCI-H526 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK0fZB3PzJiaB?= M3zKU2ROW09? M1GwWWlEPTB;MT6wNUDPxE1? NGHMbY8zPDlyNEm2NS=>
TT M1XGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HqV|czKGh? MkC1SG1UVw>? NEHV[ohKSzVyPUCuNFQh|ryP M2q2eFI1QTB2OU[x
EoL-1-cell NYn0fWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwNkSgdG0> NXG3NVFxW0GQR1XS
MV-4-11 NVu5NlAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTVTWM2OD1{N{KgdG0> NHjTW2dUSU6JRWK=
NOS-1 NHOwTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TUZBKSzVyPUG1MlMhdk1? NVjFNpE3W0GQR1XS
CGTH-W-1 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvlZYV1UUN3ME2zNE46PCCwTR?= NIXoNFJUSU6JRWK=
MONO-MAC-6 NFvQXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN|Lkigcm0> Mlm5V2FPT0WU
ALL-PO M3jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnuWGVKSzVyPUe5Mlg6KG6P Ml\QV2FPT0WU
NKM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETDWJRKSzVyPUm4MlUzKG6P MWfTRW5ITVJ?
KM12 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTN3MD6xOEBvVQ>? MW\TRW5ITVJ?
TE-15 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVyNz62NUBvVQ>? NIfsR4lUSU6JRWK=
697 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjqfmZKSzVyPU[xOE4zPSCwTR?= M{jGWHNCVkeHUh?=
MOLT-16 NX\QfGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPlTWM2OD14M{GuN|Ihdk1? MYrTRW5ITVJ?
GB-1 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SO3dyUUN3ME23NVAvOjNibl2= MkC2V2FPT0WU
TE-12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjBRYNMUUN3ME24NFQvPTVibl2= NF3k[lBUSU6JRWK=
ES6 M{jhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjX[|FKSzVyPUm4NU4xPiCwTR?= M2rsPXNCVkeHUh?=
LC-2-ad MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPiOVhKSzVyPUGuNVE1ODdizszN NXrjSGt5W0GQR1XS
BL-70 M3fyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TOo1KSzVyPUGuNVE5PDZizszN MYXTRW5ITVJ?
ETK-1 M2HQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTxTWM2OD1zLkK4OVgh|ryP NH3Z[WNUSU6JRWK=
A4-Fuk NH\6NnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjOdI5KSzVyPUGuN|QyPDFizszN NWXXdXA3W0GQR1XS
OCI-AML2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv2ZXZKSzVyPUGuN|Y5PTFizszN NELwXWNUSU6JRWK=
SIG-M5 NVXiO2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\EbllKSzVyPUGuN|cxODlizszN MlS2V2FPT0WU
NCI-SNU-16 NH7wWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3npcmlEPTB;MT60OlQ5PiEQvF2= NGnudWxUSU6JRWK=
PSN1 NX\VTow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorWTWM2OD1zLkWwOlc3KM7:TR?= MnLmV2FPT0WU
SR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlziTWM2OD1zLkW0OVczKM7:TR?= MljWV2FPT0WU
A3-KAW NGL6OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPZXVdRUUN3ME2xMlYzPTR4IN88US=> MV3TRW5ITVJ?
KS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPyU2pKSzVyPUGuOlkzPDdizszN M1HXRnNCVkeHUh?=
CTV-1 NVnOUYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LzemlEPTB;MT63Nlc2OSEQvF2= M1jI[HNCVkeHUh?=
LB1047-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwOEG2NlQh|ryP NH\EUnNUSU6JRWK=
EMG-01 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC2ZZBGUUN3ME2xMlg{PTZ|IN88US=> MXnTRW5ITVJ?
TE-11 NIjEeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPLN2RrUUN3ME2xMlg{QTh3IN88US=> M{fuUnNCVkeHUh?=
CMK NV3tTYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\uTXpKSzVyPUGuPVU2OTdizszN M3;KVHNCVkeHUh?=
NB1 NH3zdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTneo5KSzVyPUGuPVYyOTdizszN NH\vSINUSU6JRWK=
HAL-01 NIjqR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTXTWM2OD1{LkC1PVQ3KM7:TR?= NGXUNoVUSU6JRWK=
DEL NXfTcIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pk[mlEPTB;Mj6wPFQ5OiEQvF2= M3\zSnNCVkeHUh?=
RL95-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nKS2lEPTB;Mj6xNVE{PyEQvF2= NHvNe5hUSU6JRWK=
KARPAS-299 NXjuXVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjONm1KSzVyPUKuNVE{OTNizszN MnvJV2FPT0WU
EW-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnHTWM2OD1{LkGzOVA5KM7:TR?= MVvTRW5ITVJ?
RS4-11 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H1SGlEPTB;Mj6xO|kzPCEQvF2= NYTMW|NmW0GQR1XS
BB30-HNC Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1{LkKyN|c2KM7:TR?= MVfTRW5ITVJ?
DOHH-2 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\0eGlEPTB;Mj6zN|Q{OSEQvF2= NFrpdm9USU6JRWK=
RPMI-8402 NH7WNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTNTWM2OD1{LkOzOlE5KM7:TR?= NEC4N|lUSU6JRWK=
BV-173 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPBVpFlUUN3ME2yMlM{PjZizszN NUjKXpF{W0GQR1XS
TE-10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu1TWM2OD1{LkO0N|g1KM7:TR?= Ml3FV2FPT0WU
TE-8 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G2UWlEPTB;Mj6zO|A{QCEQvF2= NIrKTY9USU6JRWK=
K052 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjEOZFPUUN3ME2yMlQxOjB{IN88US=> MnfMV2FPT0WU
KARPAS-45 M1;FXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJwNEm0OFYh|ryP Moe1V2FPT0WU
SK-NEP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP4[lRKSzVyPUKuOlAzOzdizszN MU\TRW5ITVJ?
KGN NInnTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwNkCzN|kh|ryP NWq4[5cxW0GQR1XS
ML-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuS5ZKSzVyPUKuOlM2OTJizszN MmDBV2FPT0WU
LAMA-84 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrBTWM2OD1{Lk[5OVQ2KM7:TR?= MYnTRW5ITVJ?
LXF-289 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tOYt2UUN3ME2yMlczQTh7IN88US=> NYL2VlU{W0GQR1XS
A101D MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPzTWM2OD1{Lke4N|A1KM7:TR?= MYPTRW5ITVJ?
KY821 M4i0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fWdmlEPTB;Mj63PVc2QCEQvF2= NETJVVRUSU6JRWK=
ES4 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nRfGlEPTB;Mj64NFYzQCEQvF2= MonVV2FPT0WU
SCC-3 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq2Z|lzUUN3ME2yMlgzQDlzIN88US=> M{H4T3NCVkeHUh?=
NALM-6 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomxTWM2OD1{LkmwOFc{KM7:TR?= MWDTRW5ITVJ?
BL-41 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfXTWM2OD1{LkmxNlIzKM7:TR?= MUTTRW5ITVJ?
OPM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnsPG9KSzVyPUOuNFU6PTRizszN NXfBN2RUW0GQR1XS
SF126 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf1TWM2OD1|LkC2NVk5KM7:TR?= NYXRTJFVW0GQR1XS
BE-13 M4K0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXVcVZWUUN3ME2zMlI{OTFzIN88US=> MUHTRW5ITVJ?
SF268 NHXDNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjsWIdiUUN3ME2zMlMzQDZ7IN88US=> NEXYbI9USU6JRWK=
MOLT-4 M3PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEThWYxKSzVyPUOuN|k5OzhizszN NUCxd5RXW0GQR1XS
PF-382 NWjpU4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNwNES1O{DPxE1? MoroV2FPT0WU
HEL NEjPVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEixfWVKSzVyPUOuOFgxODVizszN NX65VWF7W0GQR1XS
RPMI-6666 NWi4dZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\lTWM2OD1|LkW0NVcyKM7:TR?= M4H4SnNCVkeHUh?=
QIMR-WIL M2ruSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHsWG5KSzVyPUOuOlM{QTFizszN MVLTRW5ITVJ?
ATN-1 NFPjRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntXWNQUUN3ME2zMlY4OTF2IN88US=> MUTTRW5ITVJ?
BB49-HNC M{X6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPINmpKSzVyPUOuO|A2ODhizszN M3W5S3NCVkeHUh?=
HCE-4 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTNwN{i2OFIh|ryP M{LmbHNCVkeHUh?=
SK-LMS-1 NFvncWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETvdYtKSzVyPUOuPFM{OzhizszN NGPXdVBUSU6JRWK=
MS-1 M4\TfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwOEO3O|gh|ryP MlXRV2FPT0WU
JAR MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD1|Lkm4PFMzKM7:TR?= M{ezNHNCVkeHUh?=
KE-37 NGq4ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\BTWM2OD12LkC2NVU5KM7:TR?= NF:0fY5USU6JRWK=
LB996-RCC NEHyelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLnVYtKSzVyPUSuNVIyPjhizszN NIXlPIdUSU6JRWK=
HH MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Bb4hKSzVyPUSuNlA6OTRizszN MWLTRW5ITVJ?
HL-60 NVzzO297T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\zbWZKSzVyPUSuNlExPjVizszN MUfTRW5ITVJ?
HOP-62 NX;4TG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTQc286UUN3ME20MlM{PTJizszN NVzFZ29HW0GQR1XS
NOMO-1 NYD3UoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DBZmlEPTB;ND6zN|Y6QSEQvF2= M2[y[XNCVkeHUh?=
DU-4475 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zFNGlEPTB;ND6zOlczQSEQvF2= MXnTRW5ITVJ?
LC4-1 NYHrTmF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT6dIFKSzVyPUSuN|gxPyEQvF2= M3PyWXNCVkeHUh?=
MC116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7afnN2UUN3ME20MlQ{ODhzIN88US=> NV;GXppYW0GQR1XS
SW982 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rIVGlEPTB;ND61OVMxPyEQvF2= M{XVdnNCVkeHUh?=
SK-N-DZ NYjhXVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnJTWM2OD12Lk[3NFk6KM7:TR?= MkH4V2FPT0WU
EW-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\MdmlEPTB;ND62O|kyOSEQvF2= MX\TRW5ITVJ?
SU-DHL-1 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwOECxO|Qh|ryP NUTESW17W0GQR1XS
L-363 M1T1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;OemlEPTB;ND64NFYzOSEQvF2= NUGyXJFsW0GQR1XS
OS-RC-2 NXexUVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mxSWlEPTB;ND64O|MyKM7:TR?= NUfRSI9LW0GQR1XS
HD-MY-Z MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHVe|RpUUN3ME21MlE4OzBzIN88US=> NVn1NVFGW0GQR1XS
MHH-PREB-1 NX;OTnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTwTWM2OD13LkOyN|EzKM7:TR?= MoiyV2FPT0WU
HC-1 NFjN[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD13LkSzNlkyKM7:TR?= M{f6NHNCVkeHUh?=
SK-MM-2 NV3wdnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3PVpF2UUN3ME21MlQ4QDJizszN NUXad|U6W0GQR1XS
SH-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K5V2lEPTB;NT60PFM4KM7:TR?= NI\WTppUSU6JRWK=
MHH-CALL-2 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHidY9KSzVyPUWuO|Y4OTlizszN NEf6e4ZUSU6JRWK=
KG-1 MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwMEK4O|gh|ryP MXzTRW5ITVJ?
J-RT3-T3-5 NVfvWHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnPbHRKSzVyPU[uNFc6ODlizszN MW\TRW5ITVJ?
MMAC-SF M3TwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfYNpVtUUN3ME22MlExQTR7IN88US=> NWrrRYpxW0GQR1XS
IST-SL2 M1LCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\jfGlEPTB;Nj6xNlUyQSEQvF2= MYnTRW5ITVJ?
SW954 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPXWVh3UUN3ME22MlI4PTF5IN88US=> Mkj4V2FPT0WU
HDLM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HV[WlEPTB;Nj6zNlExQSEQvF2= MnTvV2FPT0WU
ST486 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ywW2lEPTB;Nj6zOFcyKM7:TR?= MUXTRW5ITVJ?
DG-75 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTZwNEOwOlkh|ryP Mo\KV2FPT0WU
EW-3 NXT6WZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnldnJbUUN3ME22MlQ{OjB5IN88US=> MXPTRW5ITVJ?
8-MG-BA MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljXTWM2OD14LkWxOVA4KM7:TR?= NInWPWRUSU6JRWK=
GT3TKB M12xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnKVHhKSzVyPU[uOlA4PjNizszN MnfhV2FPT0WU
KU812 NWTEWJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm4TWM2OD14Lk[5OFIh|ryP MlrMV2FPT0WU
CESS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTdwMUC0N|gh|ryP MomwV2FPT0WU
BC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TldGlEPTB;Nz6yOFgyOiEQvF2= NFX5fpJUSU6JRWK=
MZ1-PC NY[yVXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz3bXdRUUN3ME23MlMxOzh7IN88US=> M2jRPHNCVkeHUh?=
NCI-H82 NGf5[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLsW3dmUUN3ME23MlM4QDVizszN MnP0V2FPT0WU
NCI-H1355 M3zoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCVm5KSzVyPUeuOFU5ODRizszN MYTTRW5ITVJ?
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdwNUC3N|kh|ryP NVPBem1bW0GQR1XS
ARH-77 NH3jdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\iSJNKSzVyPUeuOVM2QTdizszN NG\DS2pUSU6JRWK=
MN-60 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\qNnVKSzVyPUeuOVQxQDhizszN NUSxW|hCW0GQR1XS
IMR-5 NVv2WohsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTdyNUS4O|Yh|ryP NWj6e3g{W0GQR1XS
KARPAS-422 M2C0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[xS4l4UUN3ME23MlU4OjB4IN88US=> M3e5VnNCVkeHUh?=
CA46 NYT2XodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5[5NKSzVyPUeuOVgxOTJizszN M{TJcXNCVkeHUh?=
SJSA-1 NIW1fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33mSGlEPTB;Nz62OlA3OSEQvF2= NUHsW5BJW0GQR1XS
no-11 NFvO[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvNfZRKSzVyPUeuO|c2PTdizszN MV;TRW5ITVJ?
IST-SL1 NXrreoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT2TWM2OD16LkCyOFE4KM7:TR?= M3LpNHNCVkeHUh?=
NCI-H209 NHnMfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRThwMUG2OVIh|ryP NVXzWmxpW0GQR1XS
TALL-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu5TWM2OD16LkG4N|g1KM7:TR?= M{X2SXNCVkeHUh?=
KMOE-2 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HyRmlEPTB;OD6xPVQzKM7:TR?= NIWwOXhUSU6JRWK=
HCC1599 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y5NmlEPTB;OD6xPVk5PyEQvF2= MoTLV2FPT0WU
CI-1 NXuyRlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXsR45KSzVyPUiuNlA1OTFizszN M1PtSXNCVkeHUh?=
NCI-H1304 M{exRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRThwMkC2OlEh|ryP M3vjfnNCVkeHUh?=
Daudi NHfOV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwMkO1OFYh|ryP M2r5UnNCVkeHUh?=
CPC-N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwMkmxPVkh|ryP NEDseWpUSU6JRWK=
MC-CAR M{DDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTOOWRKSzVyPUiuN|M2QCEQvF2= NGG2TVFUSU6JRWK=
SW872 M4TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\RXmlEPTB;OD6zOFc2QCEQvF2= MmO1V2FPT0WU
OVCAR-4 NH7PcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH2PHVKSzVyPUiuOVA{PTFizszN M{frUnNCVkeHUh?=
OCUB-M M1nuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTCZY1KSzVyPUiuOVY2ODhizszN NYPXbIZ[W0GQR1XS
SK-PN-DW NXLGb3p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHKTWM2OD16Lk[wPVg2KM7:TR?= NXKwSZlmW0GQR1XS
NCCIT MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwN{G3OFUh|ryP NUHYUXdvW0GQR1XS
NCI-H1648 NFHCWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\mepR7UUN3ME25MlE{QDN2IN88US=> NVryTnZYW0GQR1XS
COR-L279 NGfMNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37pfWlEPTB;OT6zPVA6KM7:TR?= NYTpO2NHW0GQR1XS
LS-123 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PtOmlEPTB;OT62PFE3OSEQvF2= M1WwfnNCVkeHUh?=
LP-1 NELYRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTlwN{iwPFMh|ryP MkfIV2FPT0WU
NB13 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrFTWM2OD17Lke5PVk1KM7:TR?= MkjkV2FPT0WU
ONS-76 NEnDRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXUTWM2OD17LkixNFE3KM7:TR?= NUX2W|VjW0GQR1XS
VA-ES-BJ MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;NXoxmUUN3ME25Mlk6QTN|IN88US=> NUDsSmVQW0GQR1XS
GR-ST NW\RNYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzKT5lKSzVyPUGwMlIzODdizszN NF\sT3dUSU6JRWK=
ES1 NVHJcYczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFyLkK5PFQh|ryP MmXuV2FPT0WU
NB14 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH3TGVKSzVyPUGwMlkzPzdizszN M3\kfnNCVkeHUh?=
Ramos-2G6-4C10 M3qyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfmd2dKSzVyPUGxMlI3PSEQvF2= Mn7oV2FPT0WU
RXF393 NGj3cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nZbmlEPTB;MUGuOFg{PCEQvF2= NF;VWodUSU6JRWK=
NCI-H2107 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTMUGdlUUN3ME2xNU42QTh2IN88US=> NYnGNZNLW0GQR1XS
K562 NGrTd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7RN4dPUUN3ME2xNU45PzB{IN88US=> NFfHfFhUSU6JRWK=
LOUCY M3vtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLkm4O|Uh|ryP M2Wxe3NCVkeHUh?=
TGBC1TKB NUX1d|ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTTd4NKSzVyPUGyMlAxOiEQvF2= NWX3VFgyW0GQR1XS
COLO-320-HSR NVz6dGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;tTWM2OD1zMj6xOVY2KM7:TR?= MXrTRW5ITVJ?
K5 NHSyNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3xVXJKSzVyPUGyMlI6QDVizszN M4DmOHNCVkeHUh?=
BC-3 NEXtRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\sZWpCUUN3ME2xNk41PjVzIN88US=> Mmi1V2FPT0WU
REH NGfjNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjCR2FKSzVyPUGyMlY1QThizszN MWTTRW5ITVJ?
NEC8 M1;xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF{Lk[4PFch|ryP NHq5T2RUSU6JRWK=
IST-MEL1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33oSGlEPTB;MUKuPFY6PCEQvF2= NVn3Xoc4W0GQR1XS
NCI-H128 M1TyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLTWM2OD1zMz6wO|I{KM7:TR?= NE\tNnNUSU6JRWK=
NCI-H1694 NFPZUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjOTWM2OD1zMz6xNVQ1KM7:TR?= NVTSboJ7W0GQR1XS
TGW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXhTWM2OD1zMz6zNlc3KM7:TR?= NUnLXWxKW0GQR1XS
NCI-SNU-1 M4LZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nVV2lEPTB;MUOuN|Q2KM7:TR?= MmL6V2FPT0WU
IST-MES1 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPl[FJMUUN3ME2xN{43PzJ7IN88US=> MX\TRW5ITVJ?
CTB-1 NHy3VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5TWM2OD1zMz63Nlk1KM7:TR?= MVvTRW5ITVJ?
HUTU-80 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[zTYN7UUN3ME2xN{44PTd|IN88US=> NYPKe2pWW0GQR1XS
LAN-6 NXryTmVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HuPGlEPTB;MUSuNlQ2PyEQvF2= NUK1b3BYW0GQR1XS
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\GWmlEPTB;MUSuNlg6PCEQvF2= NVXXUXI5W0GQR1XS
CCRF-CEM NHfqSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1zND60NVY6KM7:TR?= NYnOTFhwW0GQR1XS
NCI-H1770 NEXDTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\qOIJKSzVyPUG0MlU{PjlizszN M2DlXnNCVkeHUh?=
MZ2-MEL M{S2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m0emlEPTB;MUWuNlI2OSEQvF2= M{TuSHNCVkeHUh?=
COR-L88 NUTKdWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTvWIFQUUN3ME2xOk4xODF{IN88US=> NX3DeIVSW0GQR1XS
LOXIMVI NH7MbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF4LkK1OkDPxE1? M2PTXnNCVkeHUh?=
KALS-1 NYi5[oRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF4LkW5N|Eh|ryP M1;2R3NCVkeHUh?=
D-283MED NWfzdpY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD1zNj64OFg6KM7:TR?= M3nqNHNCVkeHUh?=
NCI-H719 M1;JWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF4LkmxOlEh|ryP NEPwV|RUSU6JRWK=
MLMA NFi5SY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17mO2lEPTB;MU[uPVkxPyEQvF2= MWLTRW5ITVJ?
EVSA-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\JSWlEPTB;MUeuNFQ5PSEQvF2= Mn7yV2FPT0WU
SK-N-FI NWTOTYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF5Lk[5NVMh|ryP NVjDNmJrW0GQR1XS
NTERA-S-cl-D1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qTWM2OD1zNz64OVczKM7:TR?= MlLzV2FPT0WU
NCI-H1882 NHLBVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;rTWM2OD1zNz65PFM1KM7:TR?= NV7hO25zW0GQR1XS
A704 NE\pV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TMNWlEPTB;MUeuPVkxPCEQvF2= MUXTRW5ITVJ?
L-428 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq3TWM2OD1zOD6wNVUyKM7:TR?= MYnTRW5ITVJ?
HCC1187 M{D4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF6LkCxPFch|ryP M3;BZ3NCVkeHUh?=
NCI-H1581 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF6LkC4OlYh|ryP M4LidXNCVkeHUh?=
BB65-RCC M{XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e1[2lEPTB;MUiuOFE3OiEQvF2= M2TSfXNCVkeHUh?=
EM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHUTWM2OD1zOD61OlczKM7:TR?= MmPIV2FPT0WU
Raji NYq5bXBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF7Lkm1OlUh|ryP MkfIV2FPT0WU
TE-1 M16wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJyLkSxNFQh|ryP NUCydHdwW0GQR1XS
SW962 NWe3b|JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjneXNpUUN3ME2yNE41Ojl|IN88US=> NU\Fco9KW0GQR1XS
MHH-NB-11 M161PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELw[mNKSzVyPUKwMlU2OjFizszN M1\tNHNCVkeHUh?=
no-10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:zNHNKSzVyPUKxMlAzPjRizszN MXnTRW5ITVJ?
GDM-1 NX24SXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm3TWM2OD1{MT65OFE1KM7:TR?= NFHXNllUSU6JRWK=
KMS-12-PE M1TPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124TWlEPTB;MkKuNlc1KM7:TR?= NHHrWnRUSU6JRWK=
NCI-H510A M3\oeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvwTWM2OD1{ND6xNlc5KM7:TR?= MUDTRW5ITVJ?
ES5 NUHoUlU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4SGlEPTB;MkSuO|M1QSEQvF2= M3n6NHNCVkeHUh?=
JiyoyeP-2003 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnQdmdwUUN3ME2yOk4zPzR{IN88US=> M164U3NCVkeHUh?=
NMC-G1 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV64XnhkUUN3ME2yO{4yQDJ{IN88US=> NE[3U4tUSU6JRWK=
NCI-H446 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ5LkS5OFYh|ryP MVTTRW5ITVJ?
NB7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDhTWM2OD1{Nz65NlI6KM7:TR?= MkXpV2FPT0WU
A388 NVnzNXlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPtNXU3UUN3ME2yPE4xODd2IN88US=> Ml\1V2FPT0WU
JVM-2 NUHTfGVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\wRZVtUUN3ME2yPE4zQDl6IN88US=> M1rqPHNCVkeHUh?=
HT-144 M4jDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4eyTGlEPTB;MkiuOlkh|ryP M2q0THNCVkeHUh?=
NCI-H747 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfSbWhKSzVyPUK4MlkyQTVizszN MVjTRW5ITVJ?
NCI-H1650 NXP5RZk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDGNJpKSzVyPUK5MlAyPzZizszN MmPJV2FPT0WU
EB-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TSXGlEPTB;MkmuOVMxQSEQvF2= M4DqSHNCVkeHUh?=
KLE MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlraTWM2OD1{OT62NVkh|ryP M3PhdnNCVkeHUh?=
TK10 NFTrc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHtO5lKSzVyPUOwMlEzPiEQvF2= MoLjV2FPT0WU
COLO-668 M4jyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjicFdKSzVyPUOwMlc6OiEQvF2= MWHTRW5ITVJ?
NCI-H23 M37ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ESIhKSzVyPUOxMlExPjNizszN M3jMOnNCVkeHUh?=
GOTO NWK3N2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\XNJpKSzVyPUOxMlYxQDVizszN MmHjV2FPT0WU
MSTO-211H NYC1c2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrpephKSzVyPUOxMlg3PzhizszN MnnUV2FPT0WU
LB831-BLC M2P4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLFSos2UUN3ME2zNk4{QDR|IN88US=> NGq2WYNUSU6JRWK=
SCH NUTzNVhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe3[|J4UUN3ME2zNk45PDh3IN88US=> MXzTRW5ITVJ?
EHEB MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN2LkGxPVMh|ryP NGO0NHVUSU6JRWK=
U-266 NGqzdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zISWlEPTB;M{SuNlc5OSEQvF2= MUjTRW5ITVJ?
EW-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WwUWlEPTB;M{SuOFczPSEQvF2= M1K4SHNCVkeHUh?=
TE-9 NXvafXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7xeWJtUUN3ME2zO{4xPDBzIN88US=> Mn3HV2FPT0WU
ES3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uxeWlEPTB;M{euOVAxPCEQvF2= MlLLV2FPT0WU
NCI-H2141 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHNTWM2OD1|OD6wPFQ{KM7:TR?= NGDTXYFUSU6JRWK=
MPP-89 M{\3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\kcIRKSzVyPUSyMlA2QDZizszN M2rzVXNCVkeHUh?=
SK-MEL-2 NIXFV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S3SGlEPTB;NEKuOlQxPSEQvF2= NGTXPZhUSU6JRWK=
LC-1F MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XzfWlEPTB;NEOuN|Y5OiEQvF2= M3\ZPHNCVkeHUh?=
NH-12 NWjnXWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTR|LkmzOVkh|ryP M4ntVHNCVkeHUh?=
RKO NXLBfFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5WpZQUUN3ME20OE4yOjV{IN88US=> NVf3dYs{W0GQR1XS
KM-H2 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvHfm9IUUN3ME20OE46PTd5IN88US=> MmTGV2FPT0WU
SK-UT-1 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m5NmlEPTB;NEmuPFgzPSEQvF2= MnjQV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products4

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID